Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
6.14
-0.17 (-2.69%)
At close: Jan 15, 2026, 4:00 PM EST
6.15
+0.01 (0.16%)
Pre-market: Jan 16, 2026, 4:12 AM EST
Nuvation Bio Employees
Nuvation Bio had 220 employees as of December 31, 2024. The number of employees increased by 169 or 331.37% compared to the previous year.
Employees
220
Change (1Y)
169
Growth (1Y)
331.37%
Revenue / Employee
$121,582
Profits / Employee
-$988,545
Market Cap
2.10B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Dec 31, 2021 | 64 | 28 | 77.78% |
| Dec 31, 2020 | 36 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NUVB News
- 2 days ago - Nuvation Bio Inc. (NUVB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 3 days ago - Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan - Business Wire
- 9 days ago - Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 5 weeks ago - Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List - PRNewsWire
- 6 weeks ago - Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 weeks ago - Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology - Business Wire
- 6 weeks ago - Nuvation Bio: A Strong Company Now Fairly Priced - Seeking Alpha